GlobeNewswire

Experts call for greater understanding of ‘bedwetting’ as a medical condition

Share
  • Bedwetting, also known as enuresis, is an uncontrollable leakage of urine while asleep1
     
  • Bedwetting is common in children, with approximately 5–10% of 7-year-olds regularly wetting their beds and the problem may persist into teenage and adulthood2
     
  • In most cases, bedwetting is a complex medical condition caused by over-production of urine at night or reduced capacity of the bladder, which can impact a child’s overall self-esteem, emotional well-being and day time functioning1 , 3

SAINT-PREX, Switzerland, May 27, 2019 (GLOBE NEWSWIRE) -- Recent survey findings highlighted there are misconceptions underlying bedwetting, a condition that is under-recognised and misunderstood by society and healthcare professionals.3,4 A frequent misconception of bedwetting is that the cause is psychological, rather than having a multifactorial pathophysiological basis.1 , 4 Furthermore, the survey revealed that not only parents but also health care providers share this misconception and treatment was not necessarily consistent with guidelines.4

“For physicians to effectively treat bedwetting, any existing behavioural issues must be managed as a separate condition,” said Dr. Michal Maternik, Department of Urology, Division of Paediatric Urology, Medical University of Gdansk, Poland. “The survey findings highlight the need for new educational initiatives to optimise the understanding of bedwetting and provision of care amongst the medical community, parents and the public.”

Bedwetting can lead to feelings of shame and low self-esteem, preventing many patients from seeking treatment.3 , 4 According to the new survey, patients and their respected caregivers reported bedwetting to be associated with behavioural difficulties including, ‘sustaining attention’ (28%), ‘maintaining attention at school’ (29%), and sleeping difficulties (21%) resulting in repercussions on school performance.4 These consequences are often prolonged as many parents seek lifestyle changes first and nearly half of them do not seek help in children five years or older.4

“For decades, bedwetting was considered as a simple condition that would resolve spontaneously,” said Professor Serdar Tekgül at the Department of Urology at Hacettepe University, Turkey. “Bedwetting is now regarded as a complex disorder involving several factors such as bladder dysfunction, and the over-production of urine at night”.

The survey was completed by physicians and patients in Alpe-Adria, Italy, Romania, Russia, Serbia and Slovakia on their understanding of the medical condition, its impact on the lives of patients and the prevalence of comorbidities.4

About Bedwetting
Bedwetting, also known as enuresis, is an uncontrollable leakage of urine while asleep in children from aged 5 years.1 In most cases it is caused by over-production of urine at night or reduced capacity of the bladder.2 An inability to wake up can be another cause.2 Bedwetting does not have a psychological cause.1 Bedwetting is a common childhood medical condition, with approximately 5–10% of 7 year-olds regularly wetting their beds and the problem may persist into teenage and adulthood.2

About World Bedwetting Day
World Bedwetting Day was initiated to raise awareness among the public and healthcare professionals that bedwetting is a common medical condition that can and should be treated. World Bedwetting Day 2019 will take place on 28th May 2019 and occurs on the last Tuesday of May each year. The theme is: ‘Time to Take Action’, in recognition that much more can be done to diagnose and treat those children who suffer from bedwetting.

For more information please visit www.worldbedwettingday.com.

About the World Bedwetting Day Steering Committee
The World Bedwetting Day Steering Committee brings together experts from across the globe to support this initiative and consists of the International Children’s Continence Society (ICCS), the European Society of Paediatric Urology (ESPU), the Asia Pacific Association of Paediatric Urology (APAPU), the International Paediatric Nephrology Association (IPNA), the European Society of Paediatric Nephrology (ESPN), the Sociedad Iberoamericana de Urologia Paediatrica (SIUP), the North American Paediatric Urology Societies, ERIC (The Children's Bowel & Bladder Charity) and Bladder & Bowel UK. The initiative is supported by Ferring Pharmaceuticals. 

1 Theunis M et al. Self-Image and Performance in Children with Nocturnal Enuresis. European Urology. 2002; 41:660-667
2 Nevéus T. Nocturnal enuresis—theoretic background and practical guidelines. Pediatr Nephrol. 2011; 26:1207–1214
3 Vande Walle J et al, Practical consensus guidelines for the management of enuresis. Eur J Pediatr 2012;171:971-983
4 Maternik. Understanding of and misconceptions around monosymptomatic nocturnal enuresis: findings from patient and physician surveys. Journal of Pediatric Urology 2018

Contact:
Emma Barrow
Emma.barrow@gcihealth.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8147ae15-92f1-41ed-a13a-b1db5f6df6ec

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

PCI Biotech: Update on the preclinical research collaboration agreement with AstraZeneca13.7.2020 19:31:34 CESTPress release

Oslo (Norway), 13 July 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced a 6 month extension of the evaluation period under its preclinical research collaboration with AstraZeneca. The collaboration was initiated in September 2015 to determine whether PCI Biotech's fimaNAc technology has the potential to enhance the delivery of AstraZeneca's nucleic acid therapeutic compounds. The evaluation of the potential for a further collaboration now runs to the end of 2020. Contact information: Per Walday, CEO pw@pcibiotech.no Mobile: +47 917 93 429 About PCI Biotech PCI Biotech is a biopharmaceutical late stage clinical development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-

EVS Broadcast Equipment reports update of share buyback program13.7.2020 17:45:00 CESTPress release

Publication on July 13, 2020, after market closing Regulated information – reporting share buyback EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVS reports update of share buyback program EVS Broadcast Equipment reports that the following transactions, conducted within the framework of the share buyback program announced on May 6, 2020, took place between July 6, 2020 and July 10, 2020. DateNumber of shares acquiredAverage price (EUR)Highest price (EUR)Lowest price (EUR)Total (EUR)06/07/20202,11216.427616.5016.36 34,695 07/07/20202,10016.507816.6216.38 34,666 08/07/20202,50016.409116.4416.30 41,023 09/07/20201,89816.363216.4216.30 31,057 10/07/20202,20216.285916.3816.24 35,862 Total10,812 16.3987 16.62 16.24 177,303 As of July 10, 2020, and since the start of the buyback program, EVS has bought 95,521 shares at an average price of EUR 15,6592, representing in total EUR 1,495,785. After aforementioned transactions the total number of ow

XBT Provider AB (Publ) Publishes Half Year Interim Report 202013.7.2020 17:30:00 CESTPress release

XBT Provider AB (Publ) Publishes Half Year Interim Report Stockholm, July 13, 2020 -- XBT Provider AB (Publ) ("XBT" or the "Company") is pleased to announce that the Interim Report for the period ended 30 June 2020 has been posted on the Company's website. The Guarantor, CoinShares (Jersey) Limited, has also provided an unaudited set, of their financial statements for the period ending on 30 June 2020, which are also posted on the Company's website. Interested persons may access an electronic copy of these documents at https://coinshares.com/etps/xbt-provider/investor-resources About XBT Provider XBT Provider AB (Publ) (XBT Provider), a CoinShares company, is the Swedish-domiciled issuer of the Bitcoin Tracker One (SE0007126024), Bitcoin Tracker Euro (SE0007525332), Ether Tracker One (SE0010296574) and Ether Tracker Euro (SE0010296582), Litecoin Tracker One (SE0011414465), Litecoin Tracker Euro (SE0011414457), XRP Tracker One (SE0011414481), XRP Tracker Euro (SE0011414473), series of c

Valmet’s comment on Alfa Laval’s tender offer for Neles’ shareholders13.7.2020 16:00:00 CESTPress release

Valmet Oyj’s press release July 13, 2020 at 5:00 p.m. EET Valmet has today become aware of Alfa Laval’s announcement on public cash tender offer for all shares in Neles. Valmet completed 14.88 percent share acquisition of Neles’ shares from Solidium Oy on July 1, 2020. “Neles is a good quality company with a strong position in the pulp and paper industry and other process industries. Valmet and Neles have a common heritage, serve similar global industries and benefit from same global megatrends. Valmet sees a good amount of value in Neles and with the previously announced share acquisition our target is to participate in developing the company further. Therefore, as a Neles shareholder, Valmet does not consider Alfa Laval’s tender offer to be beneficial for Neles. Valmet will continue as an active shareholder of Neles,” says Pasi Laine, President and CEO of Valmet. Valmet acquires 14.9% ownership in the future Neles Valmet completes 14.9% ownership acquisition of Neles VALMET Corporate

Verisk to Announce Fiscal Second-Quarter 2020 Results on August 4, 202013.7.2020 15:29:14 CESTPress release

Jersey City, NJ, July 13, 2020 (GLOBE NEWSWIRE) -- Verisk (Nasdaq:VRSK), a leading data analytics provider serving customers in insurance, energy and specialized markets, and financial services, will report its financial results for the fiscal second quarter ended June 30, 2020, on Tuesday, August 4, 2020, after the market close. The press release, with accompanying financial information, will be posted on the Verisk investor website at http://investor.verisk.com. Verisk’s management team will host a live audio webcast to discuss the financial results and business highlights on Wednesday, August 5, 2020, at 8:30 a.m. EDT (5:30 a.m. PDT, 1:30 p.m. BST). All interested parties are invited to listen to the live event via webcast on the Verisk investor website at http://investor.verisk.com. The discussion will also be available through dial-in number 1-877-755-3792 for U.S./Canada participants or 512-961-6560 for international participants. A replay of the webcast will be available for 30

CNA Transitions to AIR Worldwide as its Primary Catastrophe Risk Management Platform13.7.2020 13:02:10 CESTPress release

Boston, July 13, 2020 (GLOBE NEWSWIRE) -- Catastrophe modeling firm AIR Worldwide announced that CNA has transitioned to AIR’s Touchstone solution as its primary catastrophe risk modeling platform. AIR Worldwide is a Verisk (Nasdaq:VRSK) business. “We are excited to leverage AIR’s powerful catastrophe modeling solution to support our multiple lines of business during the underwriting process,” said Tom Stone, vice president of aggregation and catastrophe management at CNA. “AIR has a track record of providing scientifically credible models and combined with Touchstone, this complete solution will provide us with more analytics to make risk management, pricing, and risk selection decisions.” As part of the agreement, CNA is accessing Touchstone in the AIR Cloud as a secure and cost-efficient alternative to on-premise deployment. CNA is also licensing AIR’s Web Services to connect to AIR’s cloud infrastructure and obtain hazard, and loss analysis output in seconds; and Touchstone APIs to